ClinicalTrials.gg
RecruitingNCT07942558PEPROCANUpdated Nov 17, 2026

An Investigation of Fear of Progression Among Cancer Patients

An observational study in Cancer, sponsored by University of Bordeaux. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Bordeaux · Observational

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
240
Ages
18 Years and older
Sex
All
01

Study summary

This scientific study aims to better understand the fear of cancer progression and self-efficacy among people diagnosed with and treated for cancer.

The primary objective of this study is to validate two questionnaires in French among patients currently undergoing cancer treatment: one to assess fear of disease progression, and the other to assess self-efficacy in coping with cancer.

Participation involves completing an online questionnaire.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • cancer
  • Fear of Progression
  • Fear of Recurrence
  • Self-efficacy
03

In context

Neoplasms

10,832 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's planned enrollment of 240 is above the median of 200 across 2,642 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Bordeaux is the lead sponsor of 18 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Primary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be 18 years of age or older
  • Participants must have been diagnosed with cancer and be currently undergoing treatment for cancer, regardless of its location or stage.

Exclusion criteria

Exclusion Criteria:

  • Patients hospitalized in palliative care,

    • Pregnant or breastfeeding women,
    • Adults under legal guardianship (under guardianship, curatorship, or judicial protection) or who are unable to give (e.g., due to cognitive impairment),
    • Non-French speakers.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
240 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cancer patients

    Participants must have been diagnosed with cancer and be currently undergoing treatment for cancer, regardless of its location or stage.

    Other: No intervention

Interventions

  • OtherNo intervention

    This cross-sectional study uses a single assessment to evaluate all study variables through an online questionnaire. No active intervention is performed on participants. Participation involves completing this questionnaire, which comprises the following instruments : FOP-Q-SF, FCRI Severity Scale, CBI-B 2.0, WHOQOL-BREF, and GAD-7.

06

What researchers measure

Primary outcomes

  1. Fear of progression

    Questionnaire Fear of progression - Short Form (FOP-Q-SF)

    Time frame: At enrollment

  2. Fear of recurrence

    Fear of Cancer Recurrence Inventory - Short Form (FCRI-SF)

    Time frame: At enrollment

  3. Self-efficacy for coping with cancer

    Cancer Behavior Inventory - Brief (CBI-B 2.0)

    Time frame: At enrollment

Secondary outcomes

  1. Quality of life

    World Health Organisation Quality of life - Bref (WHOQOL-BREF)

    Time frame: At enrollment

  2. Anxiety

    Generalized Anxiety Disorder - 7 items (GAD-7)

    Time frame: At enrollment

07

Study locations

1 of 1 sites recruiting
  • Université de Bordeaux
    Bordeaux, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartActual
May 10, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942558
Lead sponsor
University of Bordeaux
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
May 10, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Nov 17, 2026

Study contacts

Michèle KOLECK
Contact
michele.koleck@u-bordeaux.fr
+33 5 57 57 30 34
Virginie GUILLOU
Contact
virginie.guillou@u-bordeaux.fr
+33 6 47 48 95 70
Michèle KOLECK
principal investigator · University of Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion